MOTS-c vs Humanin: Two Mitochondrial-Derived Peptides, Two Mechanisms

Two Peptides Hidden Inside a 37-Gene Genome

The human mitochondrial genome is famously small. Thirty-seven genes, catalogued decades ago, apparently all accounted for. Which makes it surprising that two of the most-studied peptides in cellular-stress research turned out to be hiding inside its ribosomal RNA genes — sequences nobody expected to carry protein-coding information. Both MOTS-c and humanin are supplied strictly for research use only, and everything below describes what has been observed in cell culture, animal models, and observational human cohorts — not outcomes in people.

If you're researching either compound, you've seen them filed under one label: mitochondrial-derived peptides, or MDPs. That grouping is accurate and slightly misleading. It suggests the two are variants of one thing, the way two GLP-1 analogs are variants of one scaffold. They aren't. Different genes, different lengths, different molecular machinery.

Two Peptides, Two Reading Frames, One Genome

Short version: both peptides are encoded inside mitochondrial ribosomal RNA genes — housekeeping genes that also, unexpectedly, carry short protein-coding stretches.

A mitochondrial-derived peptide is defined by its address rather than its chemistry. Somewhere in mitochondrial DNA sits a short open reading frame, or sORF, nested inside a gene whose job is making ribosomal RNA. That sORF gets translated, and the peptide acts as a signal. That definition is the only thing MOTS-c and humanin necessarily have in common.

Humanin came first. Three laboratories described it independently around 2001, each from a different direction — one screening for proteins that protect neurons from amyloid-beta, one studying interactions with Bcl-2-associated X protein (Bax), one working from an IGFBP3 screen. Three unrelated strategies converging on one 16S rRNA sequence is part of why it held up.

MOTS-c arrived in 2015, identified by analyzing cDNAs mapped to the 12S rRNA region in interferon-stimulated human myeloblasts. The authors confirmed the signal came from genuine mitochondrial DNA rather than nuclear mitochondrial DNA transfers, or NUMTs.

The naming trap is familiar to anyone who reads peptide literature closely: a shared category name implies shared chemistry, and often doesn't deliver. The same confusion surrounds Thymosin Alpha-1 and Thymosin Beta-4. Humanin does have genuine relatives — six small humanin-like peptides, SHLP1 through SHLP6, all read from the same 16S rRNA region. MOTS-c sits on its own.

MOTS-c: 16 Residues From the 12S rRNA Gene

In plain terms: a very short peptide, read from a 51-base-pair window inside the 12S rRNA gene, with a hydrophobic patch that does most of the mechanistic work.

Sequence and genomic address

MOTS-c is sixteen amino acids: MRWQEMGYIFYPRKLR, encoded by a 51-base-pair sORF inside MT-RNR1, the 12S rRNA gene — roughly 954 nucleotides, about 6% of mitochondrial DNA. The name is a description: mitochondrial open reading frame of the 12S rRNA type-c.

Conservation across species

The first eleven of those sixteen residues are highly conserved across fourteen mammalian species — the kind of signal that usually indicates functional constraint. But MOTS-c is absent in C. elegans and Drosophila melanogaster. The model organisms that made humanin easy to interrogate genetically don't carry MOTS-c at all.

The hydrophobic core

Residues 8 through 11 form a YIFY motif that mediates protein interactions. Substituting that hydrophobic core blocks the peptide from entering the nucleus — which tells you something important. MOTS-c isn't simply diffusing where it ends up. Something carries it, and the carrier binds that patch. Which protein does the carrying is unknown.

Humanin: A 24-Residue Helix From the 16S rRNA Gene

In plain terms: a longer peptide from a different gene, with a real secondary structure — and two legitimate published lengths depending on where in the cell it was made.

Two lengths, one gene

Humanin is encoded in MT-RNR2, the 16S rRNA gene. Translated inside the mitochondrion it runs 21 residues — MAPRGFSCLLLLTSEIDLPV. Translated in the cytosol it runs 24: MAPRGFSCLLLLTSEIDLPVKRRA. Both are correct. That matters when you compare sequences across papers, because two sources can report different lengths for the same peptide without either being wrong. Resolving that kind of ambiguity is what solution-phase structure determination exists to do.

Fold and conservation

The expressed peptide contains a three-turn alpha-helix with no symmetry — a genuine secondary structure, in contrast to MOTS-c, which the literature characterizes more by its hydrophobic motif than by any stable fold. Humanin is also the most conserved MDP described so far, appearing across nematodes, naked mole-rats, macaques, and humans. That's the opposite of MOTS-c's mammal-restricted distribution, and it shaped which experiments were possible on each.

Two engineered variants recur in humanin papers: HNG, a serine-to-glycine substitution at position 14 reported as up to 1000-fold more potent than the native peptide depending on the assay, and HNGF6A, which adds a phenylalanine-to-alanine change. Both are tool compounds built for stability in culture.

Why the Signaling Routes Diverge

The gist: humanin behaves like a hormone. MOTS-c behaves like a courier carrying mail from the mitochondrion to the nucleus.

Humanin's receptor-mediated route

Humanin binds a tripartite cell-surface complex of gp130, WSX1, and the CNTF receptor, plus formyl peptide receptor 2. Downstream it activates the AKT/ERK1/2 and STAT3 pathways — recognizable cytokine-style signaling. Inside the cell it also interacts with BAX, tBID, IGFBP3, and TRIM11, which is how the anti-apoptotic findings in neuronal culture are usually explained.

MOTS-c's receptor-less retrograde route

This is the sharpest difference between them. Reviews through 2023 note that no cellular receptor has been described for the MOTS-c peptide — a gap that sets it apart from every other characterized MDP. Rather than docking at the membrane and triggering a cascade, MOTS-c moves into the nucleus under stress and binds DNA directly: a retrograde signal, information travelling from the organelle back to the genome that encodes it. We see this pattern repeatedly in comparative peptide chemistry, where two compounds discussed as a pair turn out to have unrelated origins — much as Semax and Selank come from unrelated parent scaffolds.

Their tissue behaviour differs too. Circulating levels of both fall with age, but MOTS-c rises in skeletal muscle specifically, tracking slow-twitch fiber gene expression — a pattern humanin doesn't show.

The Folate Pathway, AICAR, and What MOTS-c Does in the Nucleus

Put simply: MOTS-c doesn't activate AMPK by touching it. It shifts a metabolite upstream, and the metabolite does the work.

The upstream metabolic squeeze

The foundational metabolomic work found that MOTS-c suppresses the folate–methionine pathway and the de novo purine biosynthesis route tethered to it. 5-methyltetrahydrofolate and methionine fall while homocysteine rises, with the folate arm suppressed first. The consequence is an accumulation of AICAR — 5-aminoimidazole-4-carboxamide ribonucleotide — which cellular kinases phosphorylate to ZMP, an AMP mimetic that binds and activates AMPK directly.

Translocation is stress-gated and AMPK-dependent

Under glucose restriction (0.5 g/L), serum deprivation (1% FBS), or oxidative challenge with tert-butyl hydrogen peroxide, MOTS-c enters the nucleus within 30 minutes and returns to a largely extranuclear state within 24 hours. Compound C or AMPK siRNA blocks the move entirely; metformin and AICAR induce it within an hour. Most tellingly, raising MOTS-c concentration without metabolic stress doesn't trigger translocation at all.

What it binds once inside

Electrophoretic mobility shift assays showed MOTS-c binding directly to antioxidant response element sequences in the promoter regions of NRF2 target genes — HO-1, NQO1, UGT1A1, UGT1A6, TXN, FTL, and GPX2. NRF2 itself co-immunoprecipitated with MOTS-c only from the nuclear extracts of stressed cells, not resting ones. RNA sequencing identified 802 genes significantly regulated when MOTS-c was overexpressed under glucose restriction: 390 up, 412 down, at a 5% false discovery rate.

The experiment that ties this together is simple. Cells overexpressing wild-type MOTS-c withstood glucose and serum restriction better than empty-vector controls; nuclear-defective mutants did not. Nuclear localization isn't incidental to the protective effect — it is the effect.

Both Peptides Fall With Age, and the Long-Lived Outliers

Short version: the most interesting human data on these peptides isn't interventional. It's observational — who happens to have more of them.

The decline

One review reports blood MOTS-c 11% and 21% higher in young people than in middle- and old-aged people; a separate review puts 70-to-81-year-olds nearly 21% below 18-to-30-year-olds. For humanin the pattern holds across species: roughly a 40% decline over a mouse's first 18 months, and a sharp fall in rhesus macaques between 19 and 25 years of age.

The outliers

The exceptions are where it gets interesting. The naked mole-rat — a rodent with negligible senescence — carries humanin roughly four-fold higher than young mice and shows only a statistical trend toward decline across its lifespan (p=0.08). In humans, children of centenarians (n=18) have significantly higher humanin than age-matched controls (n=19). And in C. elegans, humanin overexpression extended average lifespan from 17.7 to 19.0 days (p<.05), dependent on daf-16/FOXO.

The MOTS-c genetic angle

MOTS-c has its own longevity thread, and it's genetic. A mitochondrial DNA polymorphism in the MOTS-c reading frame, m.1382A>C, produces a Lys14Gln substitution at position 14. Two prediction metrics flag it as consequential: a Grantham value of 53, above the 50 threshold separating radical from conservative amino acid replacements, and a PROVEAN score of -4.000 against a -2.5 neutral cutoff. The variant is specific to Northeast Asian populations and sits in haplogroup D4b2, which earlier work associated with extended lifespan in Japanese cohorts. Read that carefully, though — it's an association from a population-genetics study of centenarians, and the authors describe it as a proposed link requiring further work.

What the Research Does and Does Not Establish

The gist: both peptides are far better characterized as biology than as anything with a defined application.

Open mechanistic questions

How MOTS-c crosses into cells intact is unverified; nuclear entry requires those hydrophobic groups, which implies helper proteins nobody has identified. The 2023 review surveying its therapeutic potential states plainly that no effective method of applying MOTS-c in the clinic has been developed and that human trials remain absent. For humanin the receptor biology is better mapped, but the gap between a mapped receptor and a defined application is still wide.

Context-dependence cuts both ways

Humanin is protective in neurodegeneration models — and the same peptide has been reported to impair chemotherapy and promote tumour progression in breast cancer and glioblastoma models. Within the humanin-like family, SHLP6 induces apoptosis in multiple cell lines where its siblings are cytoprotective. "Cytoprotective," in other words, isn't a context-free property of a molecule.

Replication and cohort inconsistency

The human cohort data doesn't line up cleanly either. Obese male children and adolescents aged 5 to 14 showed MOTS-c levels 20.3% lower than comparison groups, while a study of adults aged 31 to 38 found no correlation between body mass index and plasma MOTS-c. That's the pattern that makes why independent replication matters the central question for any emerging compound literature. Both compounds are research-grade material only, and correlational data does not support outcome claims.

Frequently Asked Questions

What is the structural difference between MOTS-c and humanin?

Length, origin, and fold. MOTS-c is 16 residues (MRWQEMGYIFYPRKLR) from a 51-base-pair sORF inside the 12S rRNA gene MT-RNR1. Humanin comes from a different gene, the 16S rRNA gene MT-RNR2, and exists at 21 residues when made inside the mitochondrion or 24 (MAPRGFSCLLLLTSEIDLPVKRRA) in the cytosol. Humanin folds into a three-turn alpha-helix; MOTS-c has no comparable stable fold.

Are MOTS-c and humanin related to each other?

Only by category, not by sequence. Both are encoded by short open reading frames hidden inside mitochondrial rRNA genes rather than in nuclear DNA — but they come from different rRNA genes, share no sequence homology, and engage different molecular partners. The six small humanin-like peptides (SHLP1 through SHLP6) are genuinely related to humanin. MOTS-c is not.

Why does MOTS-c have no identified receptor?

On current evidence it doesn't appear to need one in the conventional sense. Humanin acts like a secreted signaling molecule, binding a tripartite receptor of gp130, WSX1, and CNTFR plus formyl peptide receptor 2. MOTS-c behaves as a retrograde signal instead: in cell culture it moves into the nucleus under metabolic stress and binds DNA directly at antioxidant response elements. How it crosses membranes without degradation remains unverified.

Do MOTS-c and humanin levels change with age?

Both decline in circulation across the published cohorts. Blood MOTS-c runs roughly 11% and 21% lower in middle-aged and older people than in young people. Humanin shows a comparable pattern — about a 40% drop over a mouse's first 18 months, and a sharp fall in rhesus macaques between 19 and 25 years. The informative exception is the naked mole-rat, which holds humanin four-fold higher than young mice with only a non-significant downward trend.

Has either peptide been studied in humans clinically?

No. The evidence base is cell culture, rodent work, and observational cohorts that measure circulating peptide levels against age or metabolic markers. A 2023 review states plainly that no effective method of applying MOTS-c in the clinic has been developed and that human trials remain absent. Both compounds are supplied for research use only.

The Bottom Line

MOTS-c and humanin share a category and a genome. They don't share a mechanism. One signals outward through a cell-surface receptor complex and recognizable kinase cascades; the other carries stress information inward, into the nucleus, where it binds DNA at antioxidant response elements. Collapsing them into one bucket called "mitochondrial peptides" throws away the part that makes each worth studying. The most durable findings so far are descriptive — where each peptide comes from, what it binds, how its levels track with age. The interventional questions remain open.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.